Kala Pharmaceuticals
A biopharmaceutical company that develops nanotherapeutic treatments for ocular diseases and other eye related conditions
All edits
' fill='white' fill-rule='nonzero'%3e%3cpath d='M52 12c-22.048 0-40 17.952-40 40 0 10.848 4.48 21.376 12.288 28.864 7.008 6.752 16.096 10.592 25.792 11.04.48.032.992.096 1.472.096H52c10.336 0 20.128-3.904 27.616-11.04C87.616 73.312 92 63.04 92 52c0-22.048-17.952-40-40-40zm26.912 65.056c-1.472-5.216-8.448-8.032-13.696-10.112l-1.792-.736C60 64.8 60 63.488 60 61.6c0-1.344.672-3.264 1.888-4.416 3.104-2.72 4.736-6.464 4.736-10.816 0-8.8-6.144-15.168-14.624-15.168-8.448 0-14.336 6.24-14.336 15.168 0 4.544 1.536 8.192 4.512 10.816 1.248 1.12 1.792 3.072 1.792 4.416 0 1.344 0 3.008-4.16 4.704-5.12 2.112-11.904 4.992-15.008 10.432C18.688 69.984 15.2 61.12 15.2 52c0-20.288 16.512-36.8 36.8-36.8 20.288 0 36.8 16.512 36.8 36.8 0 9.408-3.52 18.208-9.888 25.056z'/%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
April 13, 2016
On April 13, 2016 Kala Pharmaceuticals completed their series C funding round with $68 million in funding from Longitude Capital (lead investor), Wellington Management, Vivo Capital, RA Capital Management, Polaris Partners, Lux Capital, and CAM Capital.
April 23, 2014
On April 23, 2014 Kala Pharmaceuticals completed their series B funding round with $22.5 million in funding from Ysios Capital (lead investor), Third Rock Ventures, Polaris Partners, Lux Capital, Crown Venture Fund, and AbbVie Biotech Ventures.
On April 23, 2014 Kala Pharmaceuticals completed their series B funding round with $22.5 million in funding from Ysios Capital (lead investor), Third Rock Ventures, Polaris Partners, Lux Capital, Crown Venture Fund, and AbbVie Biotech Ventures.
On April 13, 2016 Kala Pharmaceuticals completed their series C funding round with $68 million in funding from Longitude Capital (lead investor), Wellington Management, Vivo Capital, RA Capital Management, Polaris Partners, Lux Capital, and CAM Capital.
Find more companies like Kala Pharmaceuticals
